



POSTER PRESENTATION

Open Access

# Disorders of the cMyb proto-oncogene expression and its significance in the course of ATL development

Kazumi Nakano<sup>1\*</sup>, Atae Utsunomiya<sup>2</sup>, Kazunari Yamaguchi<sup>3</sup>, Kaoru Uchimarū<sup>4</sup>, Toshiki Watanabe<sup>1</sup>

From 16th International Conference on Human Retroviruses: HTLV and Related Viruses  
Montreal, Canada. 26-30 June 2013

Accumulation of genetic disorders in HTLV-1 infected cells underlies ATL leukemogenesis, yet the actual genetic events responsible for cellular transformation have not been fully elucidated. Based on gene expression profiling in 52 ATL patients, 40 HTLV-1 carriers, and 21 healthy volunteers, we determined several potential risk-indicator genes of ATL, including cMyb. cMyb is the proto-oncogene of vMyb, the oncoprotein of avian myeloblastosis virus, governing hematopoietic cell differentiation. Required for differentiation of DN3, survival of DP, and generation of CD4<sup>+</sup>-SP cells, cMyb is not expressed at a detectable level in mature T-cells. Among well-known 7 isoforms, cMyb-9A and -10A, lacking the *cis*-acting negative regulatory domain (NRD) same as vMyb oncoprotein, are known to be molecules of “gain of oncogenic function”. We demonstrated that the mRNA levels of *cmyb-9a* and *-10a* were drastically elevated in ATL cells. Moreover, cMyb-9A protein was overexpressed in PBMC of HTLV-1 carriers and ATL patients. cMyb-9A showed the highest transactivation of HTLV-1 LTR, which is one of the cMyb targets, among 7 isoforms. The level of cMyb is known to be regulated by SUMOylation through the NRD. As expected, SUMOylation assay showed that cMyb-9A was not effectively SUMOylated, and its activity was not suppressed. Finally, cMyb-9A exhibited a significantly higher transforming activity than WT-cMyb. Upon confirming that cMyb-9A is released from the negative-regulatory circuit of cMyb, we speculate that overexpression of cMyb-9A in HTLV-1 infected cells has a strong link to disorders in cellular homeostasis by overruling its target gene expression, thus accelerating transformation process to ATL.

#### Authors' details

<sup>1</sup>Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan. <sup>2</sup>Department of Hematology, Imamura Hospital Bun-in, Kagoshima, Japan. <sup>3</sup>Department of Safety Research on Blood and Biologics, National Institute of Infectious Diseases, Tokyo, Japan. <sup>4</sup>Department of Hematology and Oncology, Research Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Published: 7 January 2014

doi:10.1186/1742-4690-11-S1-P94

**Cite this article as:** Nakano *et al.*: Disorders of the cMyb proto-oncogene expression and its significance in the course of ATL development. *Retrovirology* 2014 **11**(Suppl 1):P94.

Submit your next manuscript to BioMed Central  
and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)



<sup>1</sup>Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan  
Full list of author information is available at the end of the article

